|Basis of Allotment|
(THIS IS ONLY AN ADVERTISEMENT FOR INFORMATION PURPOSE AND NOT A PROSPECTUS ANNOUNCEMENT.)
M K PROTEINS LIMITED
CIN No.: U15500HR2012PLC046239
Our Company was incorporated as M K Proteins Private Limited under the provisions of the Companies Act, 1956 vide certificate of incorporation dated June 15, 2012. Subsequently, our Company was converted into public limited company and the name of our Company was changed to "M K Proteins Limited" pursuant to shareholder's resolution dated January 20,2017 and vide fresh certificate of incorporation dated February 08,2017. For further details, please refer to chapter titled 'Our History and Certain Other Corporate Matters' beginning on page 115 of the Prospectus.
Registered Office: Naraingarh Road, Vill. Garnala Ambala City, Haryana -134003. | Tel No.: +91 171 2679157,2679358 | Email: firstname.lastname@example.org Website: www.mkproteins.in | Contact Person: Mr. Vinod Kumar, Managing Director
Promoters of Our Company: Mr. Vinod Kumar, Mr. Raj Kumar,
BASIS OF ALLOTMENT
PUBLIC ISSUE OF 14,62,000 EQUITY SHARES OF FACE VALUE OF RS 10 EACH FULLY PAID UP OF M K PROTEINS LIMITED ("MKP" OR THE "COMPANY" OR THE "ISSUER") FOR CASH AT A PRICE OF RS 70 PER EQUITY SHARE (THE "ISSUE PRICE") (INCLUDING A SHARE PREMIUM OF RS 60 PER EQUITY SHARE AGGREGATING RS 1023.40 LAKHS (THE "ISSUE") BY OUR COMPANY OF WHICH 74,000 EQUITY SHARES OF RS 10 FULLY PAID UP EACH WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF 13,88,000 EQUITY SHARES OF RS 10 EACH FULLY PAID UP IS HEREINAFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE WILL CONSTITUTE 35.05% OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF THE COMPANY
THIS ISSUE IS BEING IN TERMS OF CHAPTER XB OF THE SEBI (ICDR) REGULATIONS, 2009 (AS AMENDED FROM TIME TO TIME). FOR FURTHER DETAILS PLEASE REFER TO "SECTION VII - ISSUE INFORMATION" BEGINNING ON PAGE 239 OF THE PROSPECTUS.
THE FACE VALUE OF THE EQUITY SHARES IS RS 10 EACH.
The Equity Shares offered through the Prospectus are proposed to be listed on the
NSE Emerge Platform ("NSE"). The Company has received an in-principle approval
letter dated March 17,2017 from NSE for using its name in the offer document for listing
of its shares on NSE Emerge Platform.
The Issue has received 237 applications for 17,42,000 Equity Shares resulting in 1.19
times subscription (including reserved portion of Market Maker). The details of the
applications received and banked in the Issue (before technical rejections) are as
The details of applications rejected by the Registrar on technical grounds are detailed below: (Technical rejection)
After eliminating technically rejected applications, the following tables give us Category wise net valid applications:
Allocation: The Basis of Allotment was finalized in consultation with the Designated Stock Exchange - National Stock Exchange of India Limited on April 12,2017.
A. Allocation to Market Maker (After Technical Rejections): The Basis of Allotment to the Market Maker, at the issue price of Rs 70 per Equity Share, was finalized in consultation with NSE. The category was subscribed by 1.00 times. The total number of shares allotted in this category is 74,000 Equity Shares.
B. Allocation to Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Retail Individual Investors, at the issue price of Rs 70 per Equity Share, was finalized in consultation with NSE. The category was subscribed by 0.50 times. The total number of shares allotted in this category is 344000 Equity Shares to 172 successful applicants.
The Cateoorv-wise details of the Basis of Allotment are as under:
C. Allocation to Other than Retail Individual Investors (After Technical Rejections): The Basis of Allotment to the Non Institutional Investors, at the issue price of Rs 70 per Equity Share, was finalized in consultation with NSE. The category was subscribed 1.89 times. The total number of shares allotted in this category is 1044000 Equity Shares to 56 successful applicants. Equity shares allotted in this category includes original reservation of 694000 equity shares and spill over from Retail Individual Investors Category of 350000 equity shares. The Category-wise details of the Basis of Allotment are as under:
The Board of Directors of the Company at its meeting held on April
12,2017 has taken on record the Basis of Allocation of Equity Shares approved by the
Designated Stock Exchange viz. National Stock Exchange of India Limited and has authorized
the corporate action for the transfer of the Equity Shares to various successful
applicants. The CAN and allotment advice and/or notices will be dispatched to the address
of the Applicants as registered with the depositories on or before April 17,2017. Further,
the instructions to Self Certified Syndicate Banks for unblocking the amount are being
processed on or prior to April 13, 2017. In case the same is not received within four
working days, investors may contact Registrar at the address given below. The Equity
Shares allocated to successful applicants are being credited to their beneficiary accounts
subject to validation of the account details with the depositories concerned. The Company
is taking steps to get the Equity Shares admitted for trading on NSE Emerge Platform
within six working days from the date of the closure of the Issue.
INVESTORS PLEASE NOTE
The details of the allotment made would also be hosted on the website of the Registrar to the Issue, BIGSHARE SERVICES PRIVATE LIMITED at www.bigshareonline.com. All future correspondence in this regard may kindly be addressed to the Registrar to the Issue quoting full name of the First/Sole applicants, serial number of the Application Form, number of shares applied for and Bank Branch where the application had been lodged and payment details at the address of the Registrar given below:
BIGSHARE SERVICES PRIVATE LIMITED
THE LEVEL OF SUBSCRIPTION SHOULD NOT BE TAKEN TO BE INDICATIVE OF EITHER THE MARKET PRICE OF THE EQUITY SHARE ON LISTING OR THE BUSINESS PROSPECTS OF M K PROTEINS LIMITED.